NCF1 and systemic lupus erythematosus: Therefore, the homozygous NCF1 p.R90H variant closely correlated with autoimmune responses in patients with SLE, and HCQ may serve as a potential drug for the treatment of NCF1 p.R90H–aggravated lupus (Supplemental Figure 14).